Evidence map›Paper›PMID 35046392›Full record

ArticleNPJ breast cancer2022

Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning.

Thomas de Bel, Geert Litjens, Joshua Ogony, Melody Stallings-Mann, Jodi M Carter, Tracy Hilton, Derek C Radisky, Robert A Vierkant, Brendan Broderick, Tanya L Hoskin and 7 more

Open access · goldAbstract read
In one paragraph

Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Field cancerization in breast cancer.The Journal of pathology · 2022
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Thomas de BelDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. thomas.debel@radboudumc.nl.ORCID http://orcid.org/0000-0003-1635-0841
Geert LitjensDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Joshua OgonyQuantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Melody Stallings-MannDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0003-3227-6063
Jodi M CarterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Tracy HiltonQuantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Robert A VierkantHealth Sciences Research, Rochester, MN, USA.
Brendan BroderickQuantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Tanya L HoskinQuantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Stacey J WinhamQuantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Marlene H FrostDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Daniel W VisscherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Teresa AllersDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Amy C DegnimDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Mark E Sherman *Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0002-9222-8808
Jeroen A W M van der Laak *Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-7982-0754
Mayo Clinic in Florida · USMayo Clinic in Arizona · USRadboud University Nijmegen · NLLinköping University · SE

Funding

Predicting Breast Cancer Risk after Benign Percutaneous BiopsyR01CA229811 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, SHERMAN, MARK E · 2018 to 2022
$3.5M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA229811NCI NIH HHS R01 CA237602
6 · The paper itself

Abstract

Convolutional neural networks (CNNs) offer the potential to generate comprehensive quantitative analysis of histologic features. Diagnostic reporting of benign breast disease (BBD) biopsies is usually limited to subjective assessment of the most severe lesion in a sample, while ignoring the vast majority of tissue features, including involution of background terminal duct lobular units (TDLUs), the structures from which breast cancers arise. Studies indicate that increased levels of age-related TDLU involution in BBD biopsies predict lower breast cancer risk, and therefore its assessment may have potential value in risk assessment and management. However, assessment of TDLU involution is time-consuming and difficult to standardize and quantitate. Accordingly, we developed a CNN to enable automated quantitative measurement of TDLU involution and tested its performance in 174 specimens selected from the pathology archives at Mayo Clinic, Rochester, MN. The CNN was trained and tested on a subset of 33 biopsies, delineating important tissue types. Nine quantitative features were extracted from delineated TDLU regions. Our CNN reached an overall dice-score of 0.871 (±0.049) for tissue classes versus reference standard annotation. Consensus of four reviewers scoring 705 images for TDLU involution demonstrated substantial agreement with the CNN method (unweighted κappa = 0.747 ± 0.01). Quantitative involution measures showed anticipated associations with BBD histology, breast cancer risk, breast density, menopausal status, and breast cancer risk prediction scores (p < 0.05). Our work demonstrates the potential to improve risk prediction for women with BBD biopsies by applying CNN approaches to generate automated quantitative evaluation of TDLU involution.

Identifiers

PMID35046392
PMCPMC8770616
OpenAlexW4205506660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.